<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291537</url>
  </required_header>
  <id_info>
    <org_study_id>CECILE 2010-020769-25</org_study_id>
    <nct_id>NCT01291537</nct_id>
  </id_info>
  <brief_title>Clinical and Economic Impact of Duodopa: Long-term Effectiveness Study in Advanced Parkinson's Disease Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      The goal of this multicentric prospective randomized controlled clinical and economic study
      is to investigate the effectiveness and cost-utility of long-term continuous intraduodenal
      infusion of levodopa ( DUODOPA), compared to best medical treatment, on advanced and severe
      form of Parkinson's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Duodopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Best medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duodopa</intervention_name>
    <arm_group_label>Duodopa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>best médical treatment</intervention_name>
    <arm_group_label>Best medical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Age&gt; 18 years and ≤ 80 years

          -  Akineto-hypertonic and/or tremor forms of Parkinson's disease as defined by the
             criteria of the French National Consensus conference for Parkinson's disease (March
             2000)

          -  Absence of parkinsonism other than a Parkinson's disease, including absence of one or
             more of the following signs: autonomic syndrome, hallucinations, pyramidal signs,
             early postural instability, early cognitive impairment (including apraxia or severe
             frontal lobe syndrome) (Consensus Conference, March 2000)

          -  Severe and advanced forms of Parkinson's disease with sensitivity to L-dopa (≥ 40%)

          -  No contraindication to Duodopa®: hypersensitivity to levodopa and carbidopa, or any of
             the excipients, angle-closure glaucoma, kidney and liver failures, severe heart
             failure, severe cardiac arrhythmia, acute stroke, pheochromocytoma, hyperthyroidism,
             Cushing syndrome, association with non-selective MAOIs and selective MAOIs-A (stop at
             least 2 weeks before initiation of Duodopa®)

          -  Fluctuations in motor performance (with OFF time ≥ 2 hours per day) and/or dyskinesia
             induced by L-DOPA altering significantly the activities of daily life in spite of an
             optimized treatment

          -  Hoehn and Yahr score &lt; 4 in best ON

          -  Ability to complete a diary of self-evaluation (with the help of another person if
             necessary)

          -  MMSE ≥ 24/30

          -  No evolutive psychosis or history of severe psychosis requiring hospitalization

          -  No digestive disease or ENT evolutionary

          -  No concomitant treatment by continuous infusion of apomorphine

          -  No concomitant treatment by deep brain stimulation

          -  No serious somatic disease likely to interfere with a good participation to the study,
             contraindication for gastrostomy

          -  Menopause proven or woman of childbearing potential with an effective contraception
             (hormonal / mechanical: oral, injectable, transdermal, implantable, intrauterine
             device, or surgery: ligation of the fallopian tubes, hysterectomy, total ovariectomy)

        Exclusion Criteria:

          -  Age &lt;18 and&gt; 80 years

          -  No signature of the informed consent form

          -  Patient with no social insurance or who cannot benefit it through a third person in
             accordance with the French law on biomedical research

          -  Population under enhanced protection (i.e minors), pregnant women, breast-feeding
             women, persons deprived of their liberty by a judicial or administrative decision,
             people in health and social service, adults under legal protection, and finally
             patients in emergency situations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CH d'Aix en Provence</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69229</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch La Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Bordeaux</name>
      <address>
        <city>Talence</city>
        <zip>33404</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <name_title>Pr Jean-Luc HOUETO</name_title>
    <organization>CHU de POITIERS</organization>
  </responsible_party>
  <keyword>Advanced</keyword>
  <keyword>Severe form</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

